Playback speed
10 seconds
SGLT-2 Inhibitors & GLP-1 RAs in CV Risk: What Have We Learned From CVOTs in T2DM? Is MACE Independent of Glucose Lowering?
By
Cardiometabolic Health Congress (CMHC)
FEATURING
Robert Eckel
By
Cardiometabolic Health Congress (CMHC)
FEATURING
Robert Eckel
0 views
January 15, 2021
Comments 0
Login to view comments.
Click here to Login